Squarepoint
KYTX icon

Squarepoint’s Kyverna Therapeutics KYTX Stock Holding History

Squarepoint’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.27M Buy
146,978
+8,110
+6% +$67.6K ﹤0.01% 2570
2025
Q4 		$1.31M Buy
+138,868
New +$1.03M ﹤0.01% 2391
2025
Q3 		– Sell
-29,730
Closed -$91.3K – 5109
2025
Q2 		$91.3K Buy
+29,730
New +$73.5K ﹤0.01% 4191
2025
Q1 		– Sell
-11,488
Closed -$43K – 5562
2024
Q4 		$43K Buy
+11,488
New +$55K ﹤0.01% 4868
2024
Q2 		– Sell
-88,423
Closed -$2.2M – 4747
2024
Q1 		$2.2M Buy
+88,423
New +$2.47M ﹤0.01% 2026

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Squarepoint's KYTX Position: Q1 2026 in Review

Squarepoint increased its Kyverna Therapeutics (KYTX) stake by 5.8% in Q1 2026, buying an estimated $67.6K and bringing the position to 146,978 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2570.

Squarepoint first reported a position in KYTX in Q1 2024 and has held it in 5 quarters since. The position peaked at $2.2M in Q1 2024. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Squarepoint held 146,978 shares of Kyverna Therapeutics worth $1.27M as of Q1 2026.
  • Squarepoint bought 8,110 Kyverna Therapeutics shares in Q1 2026, an estimated $67.6K.
  • Kyverna Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2570 holding.
  • Squarepoint first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • Squarepoint's Kyverna Therapeutics position peaked at $2.2M in Q1 2024.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.